“Neoadjuvant Durvalumab Alone Has Similar Efficacy to Durvalumab Plus Radiation in NSCLC: A Study on Biomarkers of Response and Recurrence”

https://pubmed.ncbi.nlm.nih.gov/38114518

The study found that neoadjuvant durvalumab plus radiation or durvalumab alone had similar disease-free survival rates in stages I-III non-small cell lung cancer, and explored potential biomarkers of response and recurrence.